主页 > 医药科学 >
【drug-news】儿童首选的一种口服新剂型
Methylin Oral Solution is Child Preferred
Alliant Pharmaceuticals announces preliminary results of study on
convenience and compliance of Methylin Oral Solution for treating ADHD
ALPHARETTA, Ga., Oct. 30 /PRNewswire-FirstCall/ -- Alliant
Pharmaceuticals, Inc. a pediatric specialty pharmaceutical company, today
announced preliminary results of the company's sponsored survey on Methylin
Oral Solution. The survey, Methylin Oral Solution in ADHD Patients to
Investigate Satisfaction, Convenience and Compliance, or MOSAIC, will
evaluate Methylin Oral Solution in up to 5,000 patients at more than 500
sites.
MOSAIC studies began in the second quarter of this year with enrollment
and activity continuing through the end of this year. While final results
won't be completed until second quarter 2007, Mark Pugh, President of
Alliant Pharmaceuticals, says the results so far match early predictions.
"We're finding that utilizing oral solutions or chewable tablets as a
delivery system does improve compliance among younger patients," says Pugh.
"While we have always felt that to be the case, we are now able to solidify
our beliefs."
According to early findings in the MOSAIC study:
- 68% of the patients surveyed had difficulty swallowing tablets
- 70% preferred the oral solution to a patch as a medication delivery
system
- 77% of patients indicated they liked the taste of the oral solution
- None of the respondents preferred the patch
- A 91% improvement in compliance resulted from taking the oral
medication.
Methylin Oral Solution contains methylphenidate HCL and has long been
considered a gold standard for therapy in the management of ADHD. Methylin
Oral Solution is the only liquid medication for ADHD. The oral solution
represents a significant advance in the management of ADHD in the patients
who have difficulty swallowing tablets or who prefer an easy-to-take liquid
formulation.
In gathering patients for the study, Alliant Pharmaceuticals reached
out to physicians to select and enroll their patients. All enrolled were
given Methylin Oral Solution during the 30-day survey period. After 30
days, physicians fill out a questionnaire with the patient and submit the
results to Alliant.
"The goal of the survey is to make sure we're providing our younger
patients with delivery systems that work best for them," adds Pugh. "With
children taste, as well as ease of administering, are key factors in
ensuring compliance."
Final data for the MOSAIC study will be compiled and evaluated for
release in 2007.
About Alliant Pharmaceuticals, Inc.
Alliant Pharmaceuticals, Inc. is a Specialty Pharmaceutical company
formed to develop and market a portfolio of innovative pharmaceutical
products to pediatricians and pediatric specialty physicians. Alliant
Pharmaceuticals focuses on identifying opportunities to acquire and enhance
the market potential of innovative, commercially available therapeutics and
late-stage development drugs to fulfill unmet medical needs. Additional
information about Alliant Pharmaceuticals in available online at:
http://www.alliantpharma.com.
Contact:
Sharon Kraun Tel: 678.468.0064
Email: skraun@bellsouth.net 认领此篇
如本人在48小时内,未提交其他战友可自由认领 Methylin是商品名，Alliant Pharmaceuticals出品的。
经查询该品种的主要成分是methylphenidate。
Methylphenidate，有翻译为哌醋甲酯,（国内有上市片剂，商品名为匹莫林, Pemolin），主要用于治疗儿童多动症。
另有信息，McNeil Consumer & Specialty Pharmaceuticals公司的盐酸哌甲酯（Methylphenidate HCl，Concerta）C II缓释片收到美国FDA的批准信，该药将用于治疗青少年注意力缺乏和多动症（ADHD）。 Methylin盐酸哌甲酯口服溶液是可能儿童优先选择的制剂
Alliant 公司宣布了Methylin（盐酸哌甲酯）用于治疗儿童多动症（ADHD）服用方便性与顺应性研究的初步结果。
信息来源：ALPHARETTA，Ga., / PRNewswire-FirstCall/ 日期：10月30日
Alliant 制药公司是一家专门从事儿童药物研究的公司。今天他们公布了公司
对盐酸哌甲酯口服溶液研究的初步结果。
该研究在超过5000个病人，超过500个实验点进行，目的是为了评价盐酸哌甲酯口服溶液
治疗ADHD病人的安全性、服药的方便性，病人的顺从性，或者称该研究为MOSAIC。
MOSAIC 研究的病例招募活动于今年的第二季度开始，这个征集活动一直将持续到今年年末。
虽然整个实验的最后结果到2007年第二季度也不能完成，但是Mark Pugh ，Aliant 制药公司的总裁声称这个初步结果与早期预测的相符合，“我们发现利用口服溶液剂或者咀嚼片作为给药系统可以提高儿童患者的顺应性，”pugh 还说，“这正如我们所期望的一样，现在我们可以坚定我们的信念。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-15 05:11
医学,生命科学网